Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Kyowa Kirin Co., Ltd. currently has 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 7 distinct examiners, meaning each examiner is handling a separate matter. Furthermore, the actions are located in 7 distinct art units, indicating that the company's pharmaceutical interests span a variety of technical classifications. This high degree of technical and personnel diversity requires the applicant to manage separate prosecution tracks while maintaining a consistent overall strategy.
HUI, SAN MING R is the busiest examiner for this portfolio, currently managing 1 busiest examiner pending office action. Because the 7 distinct examiners are each handling a portion of the workload, the prosecution is distributed across the pool. The number of examiners and the variety of art units requires a coordinated strategy to ensure consistency across applications while navigating the different perspectives of separate officials. Practitioners should be aware that the distribution across many examiners and 7 distinct art units may lead to varying timelines and examination standards for the pending matters. The broad focus within the biotechnology field is evident from this diverse administrative footprint.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (29%) |
| §102 only | 1 (14%) |
| Double-patenting only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUI, SAN MING R | 1 | 59.6% | +20.0% |
| CALDERON, DAVID ANDREW | 1 | 100.0% | +0.0% |
| TICHY, JENNIFER M.H. | 1 | 64.6% | +34.4% |
| STEPHENS, AMELIA CAROLE | 1 | 75.0% | +50.0% |
| SIMMONS, CHRIS E | 1 | 34.2% | +19.6% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| DEBERRY, REGINA M | 1 | 50.2% | +30.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18534162 | SYNTHETIC ADSORBENT, ANTIBODY PURIFICATION METHOD, AND ANTIBODY PRODUCTION METHOD | CALDERON, DAVID ANDREW | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17916275 | ANTIBODY COMPOSITION | BRISTOL, LYNN ANNE | 59d overdue |
| 18248238 | METHOD FOR TREATING OX40 RELATED DISEASE | STEPHENS, AMELIA CAROLE | 49d overdue |
| 18598208 | PHARMACEUTICAL COMPOSITION | HUI, SAN MING R | — |
| 18287750 | METHOD FOR SUPPRESSING PRODUCTION OF DEGRADATION PRODUCTS | TICHY, JENNIFER M.H. | — |
| 18118898 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | SIMMONS, CHRIS E | — |
| 17288057 | PHARMACEUTICAL COMPOSITION FOR TREATING APLASTIC ANEMIA | DEBERRY, REGINA M | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1742 | 1 |
| 1653 | 1 |
| 1645 | 1 |
| 1622 | 1 |
| 1643 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18598208 | PHARMACEUTICAL COMPOSITION | HUI, SAN MING R | 1627 | DP | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18534162 | SYNTHETIC ADSORBENT, ANTIBODY PURIFICATION METHOD, AND ANTIBODY PRODUCTION METHOD | CALDERON, DAVID ANDREW | 1742 | §102§112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18287750 | METHOD FOR SUPPRESSING PRODUCTION OF DEGRADATION PRODUCTS | TICHY, JENNIFER M.H. | 1653 | §102 | Final Rejection | — | Pending | Oct 20, 2023 |
| 18248238 | METHOD FOR TREATING OX40 RELATED DISEASE | STEPHENS, AMELIA CAROLE | 1645 | §103 | Non-Final OA | 49d overdue | Pending | Apr 06, 2023 |
| 18118898 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | SIMMONS, CHRIS E | 1622 | §112DP | Non-Final OA | — | Pending | Mar 08, 2023 |
| 17916275 | ANTIBODY COMPOSITION | BRISTOL, LYNN ANNE | 1643 | §103DP | Final Rejection | 59d overdue | Pending | Sep 30, 2022 |
| 17288057 | PHARMACEUTICAL COMPOSITION FOR TREATING APLASTIC ANEMIA | DEBERRY, REGINA M | 1647 | §103 | Non-Final OA | — | Pending | Apr 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKyowa Kirin Co., Ltd. has 7 pending office actions as of October 2026, spread across 7 art units and 7 examiners.
San Ming R Hui has the most, with 1 of Kyowa Kirin Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
